Cargando…

Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis

The aim of this study was to assess the prevalence of cardiovascular risk factors in TAK, to describe the use of aspirin and statins and the risk factors associated with vascular ischemic complications and relapses. We conducted a retrospective study on TAK patients diagnosed between 2010 and 2018....

Descripción completa

Detalles Bibliográficos
Autores principales: Laurent, Charlotte, Prieto-González, Sergio, Belnou, Pierre, Carrat, Fabrice, Fain, Olivier, Dellal, Azeddine, Cid, Maria C., Hernández-Rodríguez, José, Mekinian, Arsène
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277815/
https://www.ncbi.nlm.nih.gov/pubmed/34257320
http://dx.doi.org/10.1038/s41598-021-93416-0
_version_ 1783722133976776704
author Laurent, Charlotte
Prieto-González, Sergio
Belnou, Pierre
Carrat, Fabrice
Fain, Olivier
Dellal, Azeddine
Cid, Maria C.
Hernández-Rodríguez, José
Mekinian, Arsène
author_facet Laurent, Charlotte
Prieto-González, Sergio
Belnou, Pierre
Carrat, Fabrice
Fain, Olivier
Dellal, Azeddine
Cid, Maria C.
Hernández-Rodríguez, José
Mekinian, Arsène
author_sort Laurent, Charlotte
collection PubMed
description The aim of this study was to assess the prevalence of cardiovascular risk factors in TAK, to describe the use of aspirin and statins and the risk factors associated with vascular ischemic complications and relapses. We conducted a retrospective study on TAK patients diagnosed between 2010 and 2018. Demographic, clinical, laboratory data and treatments were evaluated at diagnosis and during the follow-up. We included fifty-two TAK patients with median age 37.5 years [range 16–53] and 43 (83%) women. At diagnosis, cardiovascular risk factors were present in 32 (62%) patients: hypertension (n = 20, 38%), hyperlipidemia (n = 8, 15%), tobacco use (n = 16, 31%). During the median 4-year follow-up [range 0.1–17 years], 17 (33%) patients had at least one ischemic event and 15 (29%) patients needed endovascular procedure. Whereas TAK patients with cardiovascular risk factors were more frequently on statins and anti-hypertensive drugs, they have higher rates of cumulative ischemic complications (5 (24%) versus 21 (67%); p = 0.004), but similar rates of aspirin-treated patients. Patients who have developed vascular ischemic events were more frequently smokers (53% versus 20%; p = 0.03). The vascular complication-free survival was not significantly different in TAK patients with or without statins or aspirin at diagnosis. During the follow-up, 27 (52%) patients had at least one relapse, and the relapse-free survival was not significantly different in patients treated with statins or aspirin. Cardiovascular risk factors in TAK have to be strictly controlled since these risk factors could be associated with increased risk of ischemic complications.
format Online
Article
Text
id pubmed-8277815
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82778152021-07-15 Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis Laurent, Charlotte Prieto-González, Sergio Belnou, Pierre Carrat, Fabrice Fain, Olivier Dellal, Azeddine Cid, Maria C. Hernández-Rodríguez, José Mekinian, Arsène Sci Rep Article The aim of this study was to assess the prevalence of cardiovascular risk factors in TAK, to describe the use of aspirin and statins and the risk factors associated with vascular ischemic complications and relapses. We conducted a retrospective study on TAK patients diagnosed between 2010 and 2018. Demographic, clinical, laboratory data and treatments were evaluated at diagnosis and during the follow-up. We included fifty-two TAK patients with median age 37.5 years [range 16–53] and 43 (83%) women. At diagnosis, cardiovascular risk factors were present in 32 (62%) patients: hypertension (n = 20, 38%), hyperlipidemia (n = 8, 15%), tobacco use (n = 16, 31%). During the median 4-year follow-up [range 0.1–17 years], 17 (33%) patients had at least one ischemic event and 15 (29%) patients needed endovascular procedure. Whereas TAK patients with cardiovascular risk factors were more frequently on statins and anti-hypertensive drugs, they have higher rates of cumulative ischemic complications (5 (24%) versus 21 (67%); p = 0.004), but similar rates of aspirin-treated patients. Patients who have developed vascular ischemic events were more frequently smokers (53% versus 20%; p = 0.03). The vascular complication-free survival was not significantly different in TAK patients with or without statins or aspirin at diagnosis. During the follow-up, 27 (52%) patients had at least one relapse, and the relapse-free survival was not significantly different in patients treated with statins or aspirin. Cardiovascular risk factors in TAK have to be strictly controlled since these risk factors could be associated with increased risk of ischemic complications. Nature Publishing Group UK 2021-07-13 /pmc/articles/PMC8277815/ /pubmed/34257320 http://dx.doi.org/10.1038/s41598-021-93416-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Laurent, Charlotte
Prieto-González, Sergio
Belnou, Pierre
Carrat, Fabrice
Fain, Olivier
Dellal, Azeddine
Cid, Maria C.
Hernández-Rodríguez, José
Mekinian, Arsène
Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
title Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
title_full Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
title_fullStr Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
title_full_unstemmed Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
title_short Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
title_sort prevalence of cardiovascular risk factors, the use of statins and of aspirin in takayasu arteritis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277815/
https://www.ncbi.nlm.nih.gov/pubmed/34257320
http://dx.doi.org/10.1038/s41598-021-93416-0
work_keys_str_mv AT laurentcharlotte prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis
AT prietogonzalezsergio prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis
AT belnoupierre prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis
AT carratfabrice prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis
AT fainolivier prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis
AT dellalazeddine prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis
AT cidmariac prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis
AT hernandezrodriguezjose prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis
AT mekinianarsene prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis